Welcome to the Porton Newsroom
Porton Pharma Solutions Ranks Among China's Top 100 Premier Pharmaceutical Suppliers and Top 10 in ESG Competitiveness
Porton ranked among China's Top 100 Pharmaceutical Suppliers & ESG Competitiveness Top 10, offering global CDMO services & sustainable solutions.
Porton Improves in the 2025 S&P Global ESG Score
Porton scored 50 in 2025 S&P Global Corporate Sustainability Assessment. Significant progress in energy, waste, water management, climate strategy, and supply chain. Committed to green development and sustainable operations.
Porton Newsletter - October 2025 Recap
Technical Enabling
Services & Solutions
Company Events
ESG
Marketing Activities
Others
Porton Warmly Congratulates Partner XZenith on Its Listing on the Main Board of the Hong Kong Stock Exchange
Porton congratulates XZenith on its HK listing, highlighting our CDMO partnership for innovative drug development and commercialization.
Porton Unveils Porton Up 3.0 Project and Launches Quality Month Initiative, Driving Enterprise-Wide Transformation
Porton launches Porton Up 3.0 initiative at Changshou site, driving comprehensive GMP compliance, quality management, and operational excellence upgrades for CDMO partners.
Porton Newsletter - September 2025 Recap
Technical Enabling
Services & Solutions
Company Events
ESG
Marketing Activities
Others
Porton Shanghai Pudong Facility Obtained ISO 14001 and ISO 45001 Certification
Porton Pharma's Shanghai Pudong site successfully obtained ISO 14001 and ISO 45001 certifications, enhancing sustainable operations and CDMO capabilities for biotech clients.
Porton Pharma Makes China's Innovative Pharmaceuticals Decennial Honor Roll, Secures 'Industry-Leading CDMO' Title
Porton Pharma honored as Industry Leading CDMO Company for innovative drug development services. Learn more about our award and global capabilities.
Porton Congratulates Partner GenFleet Therapeutics on Its HKEX Main Board Debut
GenFleet Therapeutics listed on HKEX Main Board (2595.HK). Porton, its CDMO partner, highlights API development for Fuzerelase. Learn about the IPO success.
